Professor Patrick Kennedy is a leading London-based consultant physician and hepatologist, whose work in viral liver disease is known internationally.
Professor Kennedy trained at University College Dublin. Upon completion of his initial medical training, he undertook post-graduate training in London and was subsequently appointed as a senior lecturer at Barts and The London School of Medicine and Dentistry in 2009.
Professor Kennedy has a special interest in the management of liver disease in young people, working closely with premiership football clubs and managing liver disease in professional sports people and elite athletes from the UK and abroad.
He has produced novel work redefining disease phase in chronic hepatitis B (CHB). The main focus of his curent research work is around broadening treatment candidacy and the development of individualised treatment strategies for viral liver disease. He is widely published in the field of hepatology, with over 200 publications and 90 peer-reviewed articles, in addition to multiple book chapters, he has also edited a textbook of hepato-gastroenterology.
Additionally, Professor Kennedy is an expert advisor for the WHO and is part of the HBV clinical guideline development group. He is also a member of the European Association for the study of the liver (EASL) HBV clinical practice guidelines and has served as a member for NICE on the viral hepatitis clinical guideline committee.
Furthermore, Professor Kennedy provides expert opinion for the United Kingdom Advisory Panel (UKAP) on blood-borne viruses and is the current chair of the British Viral Hepatitis Group and former Lead for the British Association for the Study of the Liver (BASL) HBV special interest group. He works closely with industry and provides expert opinion on drug development programmes.
He is the principal Investigator for a number of investigator-led and commercial phase 1, 2 and 3, clinical trials of novel therapies in viral liver disease. At present, he leads studies on the development of novel therapies in HBV and hepatitis delta virus (HDV). In addition, he is passionate about patient education and ensuring patients play a central role in their own management. Professor Kennedy has developed HBV&Me, a management app, and a current area of his research is expanding the utility of patient management tools to improve care.